Life Biosciences

Life Biosciences just crossed the threshold the entire cellular-rejuvenation field has been chasing for a decade: on June 9, 2026 it dosed the first human ever to receive a partial epigenetic reprogramming therapy, ER-100, in a Phase 1 trial for optic neuropathies including open-angle glaucoma and NAION. That is a genuine landmark — reprogramming, long confined to petri dishes and mice, is now in a person. The science carries unusual pedigree: co-founded in 2017 by Harvard geneticist David Sinclair, the company's PER platform uses the OSK trio (OCT4, SOX2, KLF4) delivered by AAV and switched on by doxycycline over an eight-week window, building directly on Sinclair-lab work that restored vision after optic-nerve injury in rodents and non-human primates. Choosing the eye is a shrewd de-risking move — it is immune-privileged, locally dosable, and offers objective visual-function readouts, making it the ideal first proving ground for a platform that could later extend to any age-degenerated tissue. The FDA cleared the IND in January 2026, calling it among the first reprogramming therapies cleared for human testing, and an $80M Series D closed in April 2026 funds operations through the second half of 2027 and the Phase 1 completion. CEO Mehmood Khan brings large-pharma operating discipline to Sinclair's science. If ER-100 shows even a partial safety-and-signal win, Life Biosciences owns first-mover credibility in the most transformative modality in aging biology.

Reprogramming is also the modality with the field's most frightening downside: forcing adult cells back toward a younger, more plastic state is mechanistically adjacent to how cells become cancerous, and the entire dedifferentiation approach carries a teratoma-and-tumorigenesis risk that a Phase 1 safety trial exists precisely to expose. First-in-human does not mean proven — it means the hardest questions are now live, and a single serious adverse event could halt not just ER-100 but cast a shadow over every reprogramming program in the sector. The economics are punishing: an $80M Series D funds the company only into late 2027, barely through Phase 1, in a modality that will need vastly more capital and a decade-plus to reach approval, so dilutive raises are guaranteed and any data wobble makes them expensive. Choosing rare optic neuropathies like NAION — which has no approved therapy but also a small, hard-to-enroll population — means even success yields a niche indication far from the "rejuvenate the whole body" promise that justifies the valuation narrative. David Sinclair's scientific celebrity cuts both ways; his prior claims around NAD+ and resveratrol have drawn pointed skepticism, and reviewers apply extra scrutiny to his ventures. Well-funded rivals like NewLimit ($3.1B valuation) and Altos Labs (multibillion-dollar war chest) are pursuing the same biology with more capital. Being first to dose is a milestone, not a moat.